...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Surgical Oncology >Institutionalization of reconstructive lymphedema surgery in Austria-Single center experience
【24h】

Institutionalization of reconstructive lymphedema surgery in Austria-Single center experience

机译：奥地利单一中心经验中重建淋巴水肿手术的制度化

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Lymphedema surgery was not widely known in Austria before the introduction of lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) in 2014. This study shares the experience and process of establishing and institutionalizing lymphedema surgery service in Austria. Methods The purpose of introducing reconstructive lymphedema surgery in Austria was to improve lymphedema patients' quality of life and provide them surgical therapy as an adjuvant treatment to complete decongestive therapy. To initialize reconstructive lymphedema surgery in Austria, LVA and VLNT had to be presented and introduced, in the manner of branding and advertizing a new product. Surgeries were performed with quality control by standardized documentation, pre- and postoperatively. Results Aligned with branding and marketing, presentations were given externally and internally to share knowledge and experience of lymphedema surgery. Lymphedema surgery service was introduced as a new brand in the medical service in Austria. After several communications with the Austrian Health Insurance Fund and with the final application, LVA and VLNT were listed as novel surgical therapies in its 2020 reimbursement catalog. Since 2014, more than 300 lymphedema patients were consulted, and 102 reconstructive lymphedema surgeries were performed. Circumference reduction of extremities after surgery was between 20% and 43%, postoperatively. Conclusion Acceptance of surgery in lymphedema patients varies among continents, hospitals, and surgeons. Evaluation of the requirement of the surgical setup and insurance conditions for lymphedema surgery is essential to establish lymphedema surgery, providing targeted marketing and branding to spread knowledge of the novel technique and grant patients access to therapeutic treatment of their chronic disease.
机译：背景技术在2014年引入淋巴诱导（LVA）和血管化淋巴结转移（VLNT）之前在奥地利并未在奥地利众所周知。本研究分享了在奥地利建立和制定淋巴式手术服务的经验和过程。方法在奥地利引入重建淋巴水肿手术的目的是提高淋巴水肿患者的生活质量，并为他们提供手术治疗，以满足辅助治疗以完全疗效。为了在奥地利初始化重建淋巴模手术，LVA和VLNT必须以品牌和广告新产品的方式呈现和介绍并介绍和介绍。通过标准化的文件，预先和术后，通过质量控制进行手术。结果与品牌和营销对齐，介绍在外部和内部享有淋巴式手术的知识和经验。 Lymphedema手术服务被引入奥地利医疗服务的新品牌。经过几次与奥地利健康保险基金和最终申请的通信，LVA和VLNT被列为2020年报销目录中的新型手术治疗。自2014年以来，咨询了300多名淋巴米患者，并进行了102名重建淋巴水肿手术。手术后末端的周长减少在术后20％至43％之间。结论淋巴水肿患者手术的接受因各大洲，医院和外科医生而异。评估淋巴水肿手术的外科手术和保险条件的要求对于建立淋巴水肿外科至关重要，提供有针对性的营销和品牌，以传播新的技术和给予患者对其慢性疾病治疗治疗的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号